Brazil Issues Guidance For Clinical Trials Conducted During Pandemic
Requests For Studies Involving Covid 19 Products To Be Prioritized
Brazil’s medicines regulator has published advice for developers on how to proceed with ongoing clinical trials and bioequivalence studies during the current COVID-19 pandemic.
You may also be interested in...
As two Chinese-developed vaccines against COVID-19 enter the final stage of testing in Latin America and the Middle East, a lack of guidance on using data obtained outside China could potentially pose challenges to regulatory approvals at home.
The coronavirus research field may be dominated by vaccines from the likes of Oxford University/AstraZeneca and Pfizer/BioNTech, but a lot of interesting work is being done elsewhere by smaller academic and commercial projects looking at the potential of various novel antibody therapies against COVID-19.
Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.